Navigation Links
New Survey Reveals High Expectations for Popular Aesthetic Injections
Date:7/7/2009

SCOTTSDALE, Ariz., July 7 /PRNewswire/ -- Americans aren't willing to give up aesthetic injections and interest is growing, whether as a means to stay competitive in today's job market or simply to maintain a youthful image, the demand and want is strong. At the time of a recent Kelton Research* survey more than 40 percent of respondents were interested in receiving aesthetic botulinum toxin injections within the next six months.(1)

Despite clear interest, many expressed reluctance to having a botulinum toxin injection. In fact, one-third of those who had not yet received the treatment were worried that it would prevent them from being able to make natural facial expressions.(1)

Sixty-three percent of survey respondents who would ever consider receiving botulinum toxin injections cited that a guarantee of natural-looking results would influence their decision, demonstrating a desire for retaining a natural-looking face, and more natural-looking expressions following injection.(1) Other top factors included more affordable costs, longer-lasting and faster-acting results.(2)

The poll found that of the respondents who had never undergone botulinum toxin injections, 36% said that their concern about no longer having a natural look had prevented them from receiving the treatment in the past.(1) Almost 60 percent of those surveyed who had not ever received an injection stated that they'd be likely to if the cost of treatment was more affordable.(1) And, of the respondents who had botulinum toxin injections, three in ten reported not seeing noticeable results for at least a week(1) and thirty percent of polled respondents said that having immediate results, such as within 24-48 hours, would positively influence their decision to undergo treatment.(2)

According to Florida dermatologist Dr. Susan Weinkle, patients want value and rapid results at a fair price. "My patients are looking for a treatment that will not make them look obvious or overdone and they want these natural looking results fast."

They are in luck: after extensive testing and clinical results, a new Botulinum Toxin A is now on the market. Dysport(TM) has been approved by the FDA for use in the United States for the temporary improvement in the appearance of moderate to severe glabellar lines - the vertical lines between the eyebrows - in adult men and women 65 or younger.

The benefits of Dysport(TM) include:

  • Duration - results lasting up to four months
  • Demonstrated efficacy with four repeat treatments (proving results following each treatment)
  • Demonstrated safety with 12 repeat treatments
  • No evidence of neutralizing antibodies
  • Clinical trials included both subjects who have and have not previously been treated with a Botulinum Toxin. There was no difference in results among the two groups
  • Large patient population - 4,800 treatments in 2,900 patients (with an ethnically diverse population)

*About the 2009 Botulinum Toxin survey:

Sample: 600 U.S. adults ages 25-60 with a household income of $50,000 or more, including 570 females and 300 botulinum toxin users and 300 aware of at least one nonsurgical aesthetic procedure or treatment.(2)

References:

1. Kelton Research. Botulinum Toxin Survey NewsWorthy Analysis. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.

2. Kelton Research. Botulinum Toxin Survey Topline Report. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.

Important Safety Information

Dysport(TM) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in appearance of moderate to

severe glabellar lines associated with procerus and corrugator muscle activity in adult patients.

Botulinum toxin effects may spread beyond the site of local injection to produce systemic symptoms of botulism such as swallowing and breathing difficulties that can occur within hours to weeks of injection. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults, particularly in those patents who have underlying conditions that would predispose them to these symptoms. In clinical trials, the most frequently reported adverse effects (>2%) are headache, nasopharyngitis and upper respiratory tract infection.

Dysport(TM) is not recommended for children or pregnant women. Re-treatment with Dysport(TM) should be administered no more than every three months.


'/>"/>
SOURCE Medicis Aesthetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NEUTROGENA(R) and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection
2. National Survey Shows 70% of Women Have Experienced a Sexual Health Issue
3. CED/Zogby Release Survey of Business Perspectives on Healthcare Reform
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. SouthWest Benefits Association Survey Finds Employers Continue to Focus on Health and Wellness during Economic Downturn
6. Innoventz Certified to Score Both the SF-36v2 and SF-12v2 Health Surveys
7. Snoring Isn't Sexy, LLC Launches Survey to Determine Extent of Drowsy Drivers on Land, Sea and In The Air
8. CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting
9. ZoneDiet.com Survey Reveals That Body Insecurity Prevents Nearly Half (49%) of Americans From Engaging in Summer Activities
10. Recent Survey Suggests Complications with Permanent Fillers
11. URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. ... a two year study conducted by the University of Saskatchewan in partnership with ... remediating potash brine-impacted groundwater. As a part of the study, batch adsorption experiments ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with the ... for families with children receiving treatment in nearby hospitals. , Ronald McDonald House ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Harbour ... manage token assets on the Ethereum blockchain, has released their technical specifications . ... now, there has been little systematic approach for determining which offerings will garner the ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ ... was held in Syracuse, New York, where EarQ is headquartered. , Together, the ... to connect with today’s savvy consumer, and the latest in hearing technology. At ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... experts to contribute to an upcoming case studies guidebook. This guidebook offers an ... , This book will include articles, case studies and how-to’s that fall into ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... CHICAGO , May 30, 2017 Hill-Rom Holdings, ... th Annual Global Healthcare Conference on Tuesday, June 13, ... John Greisch , Hill-Rom,s president and chief executive officer, ... The live audio webcast can be accessed at ... after conclusion of the live event through September 13, 2017. ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology: